Christopher B Cooper1, Bartolome R Celli2, José R Jardim3, Robert A Wise4, Daniel Legg5, Junhai Guo5, Steven Kesten6. 1. David Geffen School of Medicine, University of California, Los Angeles, CA. Electronic address: ccooper@mednet.ucla.edu. 2. Brigham and Women's Hospital, Boston, MA. 3. Federal University of São Paulo, São Paulo, Brazil. 4. Johns Hopkins Asthma and Allergy Center, Baltimore, MD. 5. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT. 6. Cytori Therapeutics, Inc, San Diego, CA.
Abstract
BACKGROUND: Disease progression in COPD is associated with a decline in exercise performance over time. We assessed whether tiotropium might mitigate this by determining its effect on treadmill endurance time (ET) over 2 years. METHODS: This was a randomized, double-blind, placebo-controlled trial of tiotropium, 18 μg daily, in patients with COPD (FEV1/FVC < 70%; postbronchodilator FEV1 < 65%). The primary end point was ET at 90% of baseline maximum work rate at 96 weeks. Secondary end points were ET at other visits, ET by smoking status, spirometry, and St. George's Respiratory Questionnaire (SGRQ). RESULTS: A total of 519 patients wererandomized (tiotropium 260, placebo 259). Mean age was 65 years, 77% were men, 34% were continuing smokers, and mean FEV1 was 1.25 L (44% predicted). Significantly more patients discontinued placebo (hazard ratio [95% CI], 0.61 [0.44-0.83]). Baseline ET was 301 s (improvement tiotropium/placebo was 13% overall; P = .009; 18% at 48 weeks, P = .004; 13% at 96 weeks, P = .106). In patients with baseline ET between 2 and 10 min (n = 404), improvement at 96 weeks was 19% (P = .04). Current smokers had higher ET with tiotropium vs placebo (P = .018). FEV1/FVC improved with tiotropium (P < .01). SGRQ total score at 96 weeks improved with tiotropium vs placebo by 4.03 units (P = .007). CONCLUSIONS:Treadmill ET was numerically greater over 2 years with tiotropium vs placebo. However, the 96-week difference was not statistically significant. Spirometry and health status also improved with tiotropium over 2 years, attesting to the benefits of long-acting bronchodilator therapy. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00525512; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: Disease progression in COPD is associated with a decline in exercise performance over time. We assessed whether tiotropium might mitigate this by determining its effect on treadmill endurance time (ET) over 2 years. METHODS: This was a randomized, double-blind, placebo-controlled trial of tiotropium, 18 μg daily, in patients with COPD (FEV1/FVC &lt; 70%; postbronchodilator FEV1 &lt; 65%). The primary end point was ET at 90% of baseline maximum work rate at 96 weeks. Secondary end points were ET at other visits, ET by smoking status, spirometry, and St. George's Respiratory Questionnaire (SGRQ). RESULTS: A total of 519 patients were randomized (tiotropium 260, placebo 259). Mean age was 65 years, 77% were men, 34% were continuing smokers, and mean FEV1 was 1.25 L (44% predicted). Significantly more patients discontinued placebo (hazard ratio [95% CI], 0.61 [0.44-0.83]). Baseline ET was 301 s (improvement tiotropium/placebo was 13% overall; P = .009; 18% at 48 weeks, P = .004; 13% at 96 weeks, P = .106). In patients with baseline ET between 2 and 10 min (n = 404), improvement at 96 weeks was 19% (P = .04). Current smokers had higher ET with tiotropium vs placebo (P = .018). FEV1/FVC improved with tiotropium (P &lt; .01). SGRQ total score at 96 weeks improved with tiotropium vs placebo by 4.03 units (P = .007). CONCLUSIONS: Treadmill ET was numerically greater over 2 years with tiotropium vs placebo. However, the 96-week difference was not statistically significant. Spirometry and health status also improved with tiotropium over 2 years, attesting to the benefits of long-acting bronchodilator therapy. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00525512; URL: www.clinicaltrials.gov.
Authors: Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin Journal: Chronic Obstr Pulm Dis Date: 2016-11-15
Authors: Marc Miravitlles; David Price; Klaus F Rabe; Hendrik Schmidt; Norbert Metzdorf; Bartolome Celli Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-03-16
Authors: Gary T Ferguson; Matjaž Fležar; Stephanie Korn; Lawrence Korducki; Lars Grönke; Roger Abrahams; Roland Buhl Journal: Adv Ther Date: 2015-06-26 Impact factor: 3.845
Authors: Roland Buhl; François Maltais; Roger Abrahams; Leif Bjermer; Eric Derom; Gary Ferguson; Matjaž Fležar; Jacques Hébert; Lorcan McGarvey; Emilio Pizzichini; Jim Reid; Antony Veale; Lars Grönke; Alan Hamilton; Lawrence Korducki; Kay Tetzlaff; Stella Waitere-Wijker; Henrik Watz; Eric Bateman Journal: Eur Respir J Date: 2015-01-08 Impact factor: 16.671
Authors: Peter M A Calverley; Michael Könen-Bergmann; Frank Richard; Susan Bell; Jens M Hohlfeld Journal: Adv Ther Date: 2016-03-28 Impact factor: 3.845
Authors: J M Hohlfeld; A Furtwaengler; M Könen-Bergmann; G Wallenstein; B Walter; E D Bateman Journal: Int J Clin Pract Date: 2014-12-11 Impact factor: 2.503
Authors: Rüdiger Sauer; Michaela Hänsel; Roland Buhl; Roman A Rubin; Marcel Frey; Thomas Glaab Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-04-27